Imagen de Portada

Assessing bone mineral density in children and adolescents living with HIV and on treatment with tenofovir disoproxil fumarate: a systematic review

ABSTRACT Objective: To investigate the impact of tenofovir disoproxil fumarate on bone mineral density and bone mineral content in children and adolescents infected with the human immunodeficiency virus. Data source: The search procedure was performed according to the Preferred Reporting Items for S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Brennda Ferreira de Gusmão (Autor), Vinícius Vital de Oliveira (Autor), Natália Maria da Silva Santos (Autor), Luciana Costa Melo (Autor)
Formato:	Libro
Publicado:	Sociedade de Pediatria de São Paulo, 2023-11-01T00:00:00Z.
Materias:	article
Acceso en línea:	Connect to this object online.
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Effects of Tenofovir Disoproxil Fumarate on Bone Quality beyond Bone Density-A Scoping Review of the Literature
por: Tejpal Singh Hashwin Singh, et al.
Publicado: (2024)

Bone outcomes in virally suppressed youth with HIV switching to tenofovir disoproxil fumarate
por: Kate Braithwaite, et al.
Publicado: (2021)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim HJ, et al.
Publicado: (2022)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Sarah M Michienzi, et al.
Publicado: (2021)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Aida N. Kawuma, et al.
Publicado: (2023)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
por: Wissam K. Kabbara, et al.
Publicado: (2015)

Effects of Hydrochlorothiazide on Tenofovir Disoproxil Fumarate-Induced Nephrotoxicity in Rats
por: Iman G.Al-Rakhat, et al.
Publicado: (2019)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Andrew Hill, et al.
Publicado: (2018)

Long-Term Evaluation of Changes in Kidney Function after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients Living with HIV
por: Jared M. Gilbert, et al.
Publicado: (2022)

A review of Tenofovir Disoproxil Fumarate associated nephrotoxicity among People Living with HIV: Burden, risk factors and solutions
por: Edwin Sam Asirvatham, et al.
Publicado: (2024)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
por: Laura Waters, et al.
Publicado: (2021)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace N, et al.
Publicado: (2020)

Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya
por: Jillian Pintye, et al.
Publicado: (2015)

Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review
por: Iulia Baciu, et al.
Publicado: (2021)

GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice gut-microbiota-dependent anti-inflammation
por: Hao Liu, et al.
Publicado: (2019)

Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
por: Emmanouil Sinakos, et al.
Publicado: (2024)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
por: Suzuki F, et al.
Publicado: (2014)

Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India
por: Nagalingeswaran Kumarasamy, et al.
Publicado: (2018)

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study
por: Kensuke Abe, et al.
Publicado: (2024)

Comparative application of derivative spectrophotometric and HPLC techniques for the simultaneous determination of lamivudine and tenofovir disoproxil fumarate in fixed-dose combined drugs
por: Edebi N. Vaikosen, et al.
Publicado: (2023)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
por: Na Yang, et al.
Publicado: (2021)

Reverse phase-liquid chromatography assisted protocol for simultaneous determination of lamivudine and tenofovir disoproxil fumarate in combined medication used to control HIV infection: an investigative approach
por: Vaibhav S. Adhao, et al.
Publicado: (2021)

Method development and validation for multi-component analysis of lamivudine & tenofovir disoproxil fumarate in bulk drug by UV-visible spectrophotometer & RP-HPLC
por: Shweta Sharma, et al.
Publicado: (2020)

Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report
por: Ris Raihan Felim, et al.
Publicado: (2024)

Association between tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients
por: Hiroki Yagura, et al.
Publicado: (2024)

A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects
por: Kim YK, et al.
Publicado: (2017)

A new stability indicating RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulation
por: Swetha Addanki, et al.
Publicado: (2021)

Tenofovir-associated bone density loss
por: Iwen F Grigsby, et al.
Publicado: (2009)

Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials.
por: McNeil Ngongondo, et al.
Publicado: (2024)

Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis
por: Marieke Bierhoff, et al.
Publicado: (2021)

Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials
por: McNeil Ngongondo, et al.
Publicado: (2024)

Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method
por: Ramreddy Godela, et al.
Publicado: (2021)

In-utero exposure to tenofovir disoproxil fumarate pre-exposure prophylaxis and growth metrics in HIV unexposed breastfed infants in South Africa: a post hoc analysis of the CAP 016 PrEP in pregnancy RCT
por: Megeshinee Naidoo, et al.
Publicado: (2024)

Pharmacokinetic Feasibility of Stability-Enhanced Solid-State (SESS) Tenofovir Disoproxil Free Base Crystal
por: Byoung Hoon You, et al.
Publicado: (2023)

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
por: Man Li, et al.
Publicado: (2023)

Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study
por: Shinichi Hikasa, et al.
Publicado: (2019)

Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations
por: Li X, et al.
Publicado: (2021)

Anticonvulsants and Bone Mineral Density
por: J Gordon Millichap
Publicado: (1995)

Bone mineral density and content in adolescent girls.
por: Romulo Maia Carlos Fonseca, et al.
Publicado: (2011)

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
por: Hannes Lengauer, et al.
Publicado: (2020)